Patric Nelson

1.1k total citations · 1 hit paper
9 papers, 868 citations indexed

About

Patric Nelson is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Patric Nelson has authored 9 papers receiving a total of 868 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Surgery, 4 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Economics and Econometrics. Recurrent topics in Patric Nelson's work include Lipoproteins and Cardiovascular Health (6 papers), Pharmaceutical Economics and Policy (3 papers) and Diabetes Treatment and Management (3 papers). Patric Nelson is often cited by papers focused on Lipoproteins and Cardiovascular Health (6 papers), Pharmaceutical Economics and Policy (3 papers) and Diabetes Treatment and Management (3 papers). Patric Nelson collaborates with scholars based in United States, South Africa and Denmark. Patric Nelson's co-authors include Scott M. Wasserman, Robert C. Scott, Jonathan Fialkow, Robert Weiss, Joel M. Neutel, Jason C. Legg, William J. Rogers, Ransi Somaratne, Jennifer G. Robinson and Bettina S. Nedergaard and has published in prestigious journals such as JAMA, Circulation and Diabetes Care.

In The Last Decade

Patric Nelson

9 papers receiving 837 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia

2014 407 citations Jennifer G. Robinson, Bettina S. Nedergaard et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patric Nelson United States	7	734	317	310	92	91	9	868
Kate Tsirtsonis United States	5	512 0.7×	128 0.4×	227 0.7×	95 1.0×	78 0.9×	6	618
Ioanna Gouni-Berthold Germany	4	358 0.5×	108 0.3×	155 0.5×	89 1.0×	49 0.5×	6	599
Mary Elliott‐Davey United States	8	425 0.6×	125 0.4×	128 0.4×	86 0.9×	97 1.1×	8	514
Marion Cousins Canada	10	497 0.7×	126 0.4×	104 0.3×	75 0.8×	116 1.3×	11	608
Hendrik du Toit Theron United States	5	517 0.7×	222 0.7×	80 0.3×	45 0.5×	171 1.9×	6	597
Maartje E. Visser Netherlands	12	488 0.7×	397 1.3×	43 0.1×	48 0.5×	207 2.3×	13	939
Nagwa Khilla United States	5	610 0.8×	314 1.0×	110 0.4×	85 0.9×	248 2.7×	11	849
Valérie Carreau France	13	364 0.5×	150 0.5×	54 0.2×	49 0.5×	95 1.0×	22	502
Kévin Chemello France	13	315 0.4×	124 0.4×	40 0.1×	46 0.5×	114 1.3×	22	423
Stephan P. Babirak United States	7	348 0.5×	328 1.0×	59 0.2×	33 0.4×	91 1.0×	9	630

Countries citing papers authored by Patric Nelson

Since Specialization

Citations

This map shows the geographic impact of Patric Nelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patric Nelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patric Nelson more than expected).

Fields of papers citing papers by Patric Nelson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patric Nelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patric Nelson. The network helps show where Patric Nelson may publish in the future.

Co-authorship network of co-authors of Patric Nelson

This figure shows the co-authorship network connecting the top 25 collaborators of Patric Nelson. A scholar is included among the top collaborators of Patric Nelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patric Nelson. Patric Nelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Blom, Dirk, Michael J. Koren, Eli M. Roth, et al.. (2016). Evaluation of the efficacy, safety and glycaemic effects of evolocumab ( AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes Obesity and Metabolism. 19(1). 98–107. 48 indexed citations

2.

Raal, Frederick J., Patric Nelson, Gisle Langslet, et al.. (2014). PM385 Safety, Tolerability, And Efficacy Of Long-Term Administration Of Monthly AMG 145 In Subjects With Heterozygous Familial Hypercholesterolemia. Global Heart. 9(1). e139–e139. 2 indexed citations

3.

Robinson, Jennifer G., Bettina S. Nedergaard, William J. Rogers, et al.. (2014). Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia. JAMA. 311(18). 1870–1870. 407 indexed citations breakdown →

4.

Henry, Robert R., Rury R. Holman, Robert P. Giugliano, et al.. (2014). Effects of Long-Term, Monthly Administration of the PCSK9 Inhibitor Evolocumab in Patients with Dysglycemia or Metabolic Syndrome. Canadian Journal of Diabetes. 38(5). S18–S18. 2 indexed citations

5.

Robinson, Jennifer G., William J. Rogers, Bettina S. Nedergaard, et al.. (2014). Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy. Clinical Cardiology. 37(4). 195–203. 12 indexed citations

6.

Koren, Michael J., Robert P. Giugliano, Frederick J. Raal, et al.. (2013). Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia. Circulation. 129(2). 234–243. 176 indexed citations

7.

Rother, Kristina I., Lisa M. Spain, Robert Wesley, et al.. (2009). Effects of Exenatide Alone and in Combination With Daclizumab on β-Cell Function in Long-Standing Type 1 Diabetes. Diabetes Care. 32(12). 2251–2257. 106 indexed citations

8.

Nelson, Patric, Terri Poon, Xuesong Guan, et al.. (2007). The Incretin Mimetic Exenatide as a Monotherapy in Patients with Type 2 Diabetes. Diabetes Technology & Therapeutics. 9(4). 317–326. 37 indexed citations

9.

Poon, Terri, Patric Nelson, Larry Z. Shen, et al.. (2005). Exenatide Improves Glycemic Control and Reduces Body Weight in Subjects with Type 2 Diabetes: A Dose-Ranging Study. Diabetes Technology & Therapeutics. 7(3). 467–477. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact